Literature DB >> 17269921

Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes.

Maria Grazia Calvagno1, Christian Celia, Donatella Paolino, Donato Cosco, Michelangelo Iannone, Francesco Castelli, Patrizia Doldo, Massimo Frest.   

Abstract

The effects of lipid composition and preparation conditions on the physicochemical and technological properties of gemcitabine-loaded liposomes, as well as the in vitro anti-tumoral activity of various liposome formulations were investigated. Three liposome formulations were investigated: DPPC/Chol/Oleic acid (8:3:1 molar ratio, liposomes A), DPPC/Chol/DPPS (6:3:1 molar ratio, liposomes B) and DPPC/Chol/DSPE-MPEG (6:3:1 molar ratio, liposomes C). Multilamellar liposomes were prepared by using the TLE, FAT and DRV methods, while small unilamellar liposomes were obtained by extrusion through polycarbonate filters. Light scattering techniques were used to characterize liposome formulations. Loading capacity and release profiles of gemcitabine from various liposome formulations were also investigated. Caco-2 cells were used to evaluate in vitro the antitumoral activity of gemcitabine-loaded liposomes with respect to the free drug and also the intracellular drug uptake. Preparation methods and liposome lipid composition influenced both physicochemical parameters and drug delivery features. Liposomes with a size ranging from 200 nm to 7 microm were obtained. The gemcitabine entrapment was higher than that expected probably due to an interaction with the liposome lipid components. The following decreasing loading capacity order was observed: liposome B>liposome C>liposome A. Gemcitabine release from various liposome formulations is modulated by two different processes, i.e. desorption from and permeation through liposomal bilayers. MTT assay showed a greater cytotoxic effect of gemcitabine-loaded liposomes with respect to the free drug. The following decreasing anticancer activity order was observed between the various liposome formulations: liposome C>liposome A>liposome B. The increased anticancer activity is correlated to the ability of the colloidal carrier to increase the intracellular drug uptake. Due to the encouraging results and to the high liposome modularity various applications of potential therapeutic relevance can be envisaged for liposomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17269921     DOI: 10.2174/156720107779314749

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  23 in total

1.  Mild hyperthermia enhances transport of liposomal gemcitabine and improves in vivo therapeutic response.

Authors:  Dickson K Kirui; Christian Celia; Roberto Molinaro; Shyam S Bansal; Donato Cosco; Massimo Fresta; Haifa Shen; Mauro Ferrari
Journal:  Adv Healthc Mater       Date:  2015-02-26       Impact factor: 9.933

2.  Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells.

Authors:  Hongtao Xu; James Paxton; Joanne Lim; Yan Li; Wenli Zhang; Linda Duxfield; Zimei Wu
Journal:  Pharm Res       Date:  2014-03-18       Impact factor: 4.200

3.  Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity.

Authors:  Saijie Zhu; Dharmika S P Lansakara-P; Xinran Li; Zhengrong Cui
Journal:  Bioconjug Chem       Date:  2012-04-18       Impact factor: 4.774

4.  Core-shell nanoparticulate formulation of gemcitabine: lyophilization, stability studies, and in vivo evaluation.

Authors:  Deepak Chitkara; Anupama Mittal; Ram I Mahato; Neeraj Kumar
Journal:  Drug Deliv Transl Res       Date:  2014-12       Impact factor: 4.617

5.  Liposomes as multicompartmental carriers for multidrug delivery in anticancer chemotherapy.

Authors:  Donato Cosco; Donatella Paolino; Jessica Maiuolo; Diego Russo; Massimo Fresta
Journal:  Drug Deliv Transl Res       Date:  2011-02       Impact factor: 4.617

6.  Preparation, physicochemical characterization and cytotoxicity in vitro of gemcitabine-loaded PEG-PDLLA nanovesicles.

Authors:  Lin Jia; Jian-Jun Zheng; Shu-Man Jiang; Kai-Hong Huang
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

7.  Sustained zero-order release of intact ultra-stable drug-loaded liposomes from an implantable nanochannel delivery system.

Authors:  Christian Celia; Silvia Ferrati; Shyam Bansal; Anne L van de Ven; Barbara Ruozi; Erika Zabre; Sharath Hosali; Donatella Paolino; Maria Grazia Sarpietro; Daniel Fine; Massimo Fresta; Mauro Ferrari; Alessandro Grattoni
Journal:  Adv Healthc Mater       Date:  2013-07-23       Impact factor: 9.933

8.  Tumor-specific delivery of gemcitabine with activatable liposomes.

Authors:  Samantha T Tucci; Azadeh Kheirolomoom; Elizabeth S Ingham; Lisa M Mahakian; Sarah M Tam; Josquin Foiret; Neil E Hubbard; Alexander D Borowsky; Mo Baikoghli; R Holland Cheng; Katherine W Ferrara
Journal:  J Control Release       Date:  2019-07-10       Impact factor: 9.776

Review 9.  Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.

Authors:  Lars Petter Jordheim; David Durantel; Fabien Zoulim; Charles Dumontet
Journal:  Nat Rev Drug Discov       Date:  2013-06       Impact factor: 84.694

10.  Interactions of primaquine and chloroquine with PEGylated phosphatidylcholine liposomes.

Authors:  Andang Miatmoko; Ira Nurjannah; Nuril Fadilatul Nehru; Noorma Rosita; Esti Hendradi; Retno Sari; Juni Ekowati
Journal:  Sci Rep       Date:  2021-06-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.